Ascentage Pharma says a trustee bought existing shares to meet its employee plan obligations after awards vested. It calls this routine administration, so the report does not change the company’s business outlook.
This handles shares promised through an employee plan, rather than reporting a change in drug development or sales. Ascentage describes it as routine administration, so the report gives no clear reason to change how we view its business.
Follow Ascentage Pharma (AAPG) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AAPG